Successful C-RAD Presentation at AAPM
C-RAD AB with its three fully owned subsidiaries and three international sales companies are all active in the field of radiation therapy. The AAPM is the annual meeting of the American Association of Physicists in Medicine. The conference took place in Indianapolis from August 4th to August 6th. C-RAD was presenting Sentinel and Catalyst.
The AAPM is one of the largest and most important meetings within the radiotherapy community. A part of the conference is the exhibition, where companies present their products to clinical customers from the US and international foreign countries. C-RAD focused on the presentation of Sentinel and Catalyst.
The focus was to present C-RAD Systems for the application in breast cancer treatment. Breast Cancer is one of the most frequent cancer indications in western countries treated with radiotherapy. The unique combination of interactive feedback for an intuitive and accurate setup together with the breath hold solution with implemented bio feedback makes Catalyst and Sentinel as an important tool in the clinical workflow.
Tim Thurn, CEO, C-RAD AB:
“We are excited about the quality and the quantity of contacts we made at the exhibition. We can surely state, that it was the best AAPM for C-RAD. The feedback and the high interest from customers are confirming the ongoing recovery of the US radiotherapy market. Also the interest from our oem partnerships is showing the right position of the C-RAD product portfolio.”
About C-RAD
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 24 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.
For more information on C-RAD, please visit www.c-rad.com.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com